verdinexor

Action and Spectrum

Actions and Spectrum:  

Actions:  

LAVERDIA-CA1, a selective inhibitor of nuclear export, inhibits chromosome region maintenance 1 (CRM1).  

Drug Interaction

Adverse Reaction

Frequency defined  

>10%  

Bilirubinuria  

Polydipsia  

Elevated liver enzymes  

Edema  

Proteinuria  

Thrombocytopenia  

Hematuria  

Anemia  

Elevated BUN  

Hyperphosphatemia  

Monocytosis  

Lymphopenia  

Partial thromboplastin time  

Hypercalcemia  

Leukocytosis  

Neutropenia   

>10%  

Lymphadenitis  

Protein losing nephropathy  

Bruising  

Corneal opacity  

Erythema  

Nasal discharge  

Hepatomegaly  

Epistaxis  

Elevated bilirubin  

Heart block  

Hypoalbuminemia  

Arrythmias  

Black Box Warning

Black Box Warning:  

Do not use in humans. Keep away from children. Avoid contact with Laverdia-CA1. Children should not touch treated dogs’ waste or saliva. 

Contraindication / Caution

Contraindication/Caution: (Not for human use)  

Contraindications  

• Hypersensitivity  
• Dogs intended for breeding  
• Dogs < 7 months  

Cautions  

• Heart disease 
• Skin contact  
• Kidney disease 
• Liver disease 
• Hypercalcemia  
• Accidental eye exposure  
• Drug interactions 
• Pregnancy & breastfeeding  

Pregnancy / Lactation

Pregnancy/Lactation 

Pregnancy consideration:   

No data is available regarding the administration of the drug during pregnancy.  

Breastfeeding warnings:   

No data is available regarding the excretion of drug in breast milk.  

Pregnancy category:  

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.  

<b>Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  

Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.     

Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.     

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.     

Category N: No data is available for the drug under this category.  

Pharmacology

Pharmacology:  

Verdinexor inhibits Exportin 1, reducing canine tumor cell growth, and inhibits influenza virus replication both in vivo and in vitro. 

Pharmacodynamics:  

Verdinexor blocks CRM1, stopping nuclear export, especially in damaged cells like tumors, by trapping Growth Regulatory Proteins and Tumor Suppressor Proteins inside the nucleus. 

Pharmacokinetics: (dogs)  

Absorption  

Peak effect can be reached between 1.1 & 2.5 hours.  

Excretion and Elimination  

The half-life is 2-4 hours  

Adminstartion

Administration:  
Give the dog a meal before giving the medication orally. 

Patient Information Leaflet

Patient information leaflet  

Generic Name: verdinexor  

Pronounced: ver-dih-NECK-sor  

Why do we use verdinexor?  

Verdinexor is used in cancer treatment that targets exportin-1, keeping tumor-suppressor proteins inside cells to regulate cell growth & inhibit cancer cell proliferation. Ongoing research is exploring its effectiveness and potential for broader cancer therapy applications.